ITGAM and colorectal carcinoma: To determine whether the expression level of CD16 on CD11b+ myeloid cells is related to treatment efficacy of capecitabine, we collected peripheral venous blood of 134 CRC patients 6–9 months after capecitabine treatment and divided these patients into two groups, CD16+ group and CD16low/− group.